Alx oncology reports second quarter 2023 financial results and provides clinical program update

Advancing phase 2/3 aspen-06 gastric cancer trial with data update expected in q423 terminating azacitidine combination development programs: aspen-02 in mds and aspen-05 in aml continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and pd-1/pd-l1 immune checkpoint inhibitors south san francisco, calif., aug. 10, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today reported financial results for the second quarter ended june 30, 2023, and provided an update on the company's portfolio of clinical programs in development.
ALXO Ratings Summary
ALXO Quant Ranking